Trial reportPloS one2014
Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population.Vaccines · 2025Article
- A Serological Survey of Measles and Rubella Antibodies among Different Age Groups in Eastern China.Vaccines · 2024Article
- Epidemic characteristics of measles and efforts to control measles infections in Zhejiang Province, China.Epidemiology and health · 2024Article
- Development of measles-rubella surveillance health information system in the working area of health center tanjung selor, bulungan district.Journal of public health in Africa · 2023Article
- A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents.Iranian journal of public health · 2022Article
- One single-center serological survey on measles, rubella and mumps antibody levels of people in Youyang, China.Human vaccines & immunotherapeutics · 2021Article
- Sero-survey of measles virus antibodies among symptomatic children attending Abuja Teaching Hospital, Nigeria.GMS hygiene and infection control · 2021Article
- Measles Outbreak in a Rural Population in Bahar District, Hamadan Province, West of Iran in 2018.Journal of research in health sciences · 2020Article
- Seroprevalence and durability of rubella virus antibodies in a highly immunized population.Vaccine · 2019Article
- Measles, mumps, and rubella: A cross-sectional study of susceptibility to vaccine-preventable diseases among young people in India.Medical journal, Armed Forces India · 2019Article
- Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing.Scientific reports · 2018Article
- Key genes and pathways in measles and their interaction with environmental chemicals.Experimental and therapeutic medicine · 2018Article
- Meteorological factors and the incidence of mumps in Fujian Province, China, 2005-2013: Non-linear effects.The Science of the total environment · 2018Article
- Timeliness of Childhood Primary Immunization and Risk Factors Related with Delays: Evidence from the 2014 Zhejiang Provincial Vaccination Coverage Survey.International journal of environmental research and public health · 2017Article
- Immunogenicity of mumps virus vaccine candidates matching circulating genotypes in the United States and China.Vaccine · 2017Article
- Timeliness and completeness of measles vaccination among children in rural areas of Guangxi, China: A stratified three-stage cluster survey.Journal of epidemiology · 2017Article
- Seroprevalence of Measles Antibodies and Predictors for Seropositivity among Chinese Children.International journal of environmental research and public health · 2017Article
- Impact of the two-dose rubella vaccination regimen on incidence of rubella seronegativity in gravidae aged 25 years and younger.PloS one · 2017Article
- Mumps Epidemiology and Mumps Virus Genotypes Circulating in Mainland China during 2013-2015.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe reported coverage of the measles-rubella (MR) or measles-mumps-rubella (MMR) vaccine is greater than 99.0% in Zhejiang province. However, the incidence of measles, mumps, and rubella remains high. In this study, we assessed MMR seropositivity and disease distribution by age on the basis of the current vaccination program, wherein the first dose of MR is administered at 8 months and the second dose of MMR is administered at 18-24 months.
methodsCross-sectional serological surveys of MMR antibodies were conducted by collecting epidemiological data in Zhejiang province, China in 2011. In total, 1015 participants were randomly selected from two surveillance sites. Serum MMR-specific immunoglobulin G levels were tested by enzyme-linked immunosorbent assay. The geometric mean titers and seroprevalence with 95% confidence intervals (CIs) were calculated by age and gender. Proportions of different dose of vaccine by age by vaccine were also identified. Statistically significant differences between categories were assessed by the Chi-square test.
resultsOver 95% seroprevalence rates of measles were seen in all age groups except <7 months infants. Children aged 5-9 years were shown lower seropositivity rates of mumps while elder adolescences and young adults were presented lower rubella seroprevalence. Especially, rubella seropositivity was significantly lower in female adults than in male. Nine measles cases were unvaccinated or unknown vaccination history. Among them, 66.67% (6/9) patients were aged 20-29 years while 33.33% (3/9) were infants aged 8-12 months. In addition, 57.75% (648/1122) patients with mumps were children aged 5-9 years, and 50.54% (94/186) rubella cases were aged 15-39 years.
conclusionsA timely two-dose MMR vaccination schedule is recommended, with the first dose at 8 months and the second dose at 18-24 months. An MR vaccination speed-up campaign may be necessary for elder adolescents and young adults, particularly young females.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.